<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666716</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF14.06</org_study_id>
    <nct_id>NCT02666716</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients</brief_title>
  <acronym>PACIFIC</acronym>
  <official_title>Pharmacokinetics of Fluconazole Given Intravenously as Prophylaxis or Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit (PACIFIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of fluconazole are expected to be different in ICU patients compared to&#xD;
      non-ICU patients. The investigators will determine fluconazole and free fluconazole&#xD;
      concentrations in 20 ICU patients, who will get intravenous fluconazole as standard care.&#xD;
      Switching to oral/enteral fluconazol is allowed after day 3.&#xD;
&#xD;
      A full pharmacokinetic curve will be taken on day 3 of iv therapy and limited pharmacokinetic&#xD;
      curves on day 7 of iv therapy and/or on day 3 of oral therapy; trough levels will be taken&#xD;
      daily after intravenous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics of fluconazole are expected to be different in ICU patients compared to&#xD;
      non-ICU patients and healthy volunteers due to underlying disease(s). Therefore,&#xD;
      extrapolation of data from healthy volunteers and non-ICU patients is not possible.&#xD;
&#xD;
      To be able to include 20 patients within the study duration, a multi-centre approach is&#xD;
      necessary.&#xD;
&#xD;
      Patients will receive standard care, as stated in the product characteristics or according to&#xD;
      local protocols. Blood sampling for pharmacokinetic analysis will be retrieved through a&#xD;
      central venous catheter. A maximum of 62 milliliter blood in total will be drawn for this&#xD;
      study. Patients will be monitored daily during the treatment period for adverse events of the&#xD;
      study drug.&#xD;
&#xD;
      Full pharmacokinetic curves will be taken on day 3 of iv therapy. Limited pharmacokinetic&#xD;
      curves will be taken on day 7 of iv therapy. These two moments of pharmacokinetic analysis&#xD;
      will enable the determination steady state and enable the determination of intra-individual&#xD;
      variability.&#xD;
&#xD;
      As probably not all patients included will be treated with iv fluconazole for 7 days,&#xD;
      switching to oral/enteral therapy is allowed after day 3. To assess bioavailability limited&#xD;
      pharmacokinetic curves will be taken on day 3 of oral/enteral therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Days 3 and 7</time_frame>
    <description>Full pharmacokinetic curves will be taken op Day 3 and Day 7 (fluconazole).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Days 3 and 7</time_frame>
    <description>Identifying influence of body weight on the pharmacokinetics of fluconazole.</description>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Candidiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>Dose according to summary of product characteristics (SPC) or local protocols</description>
    <other_name>Diflucan</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples for determination of fluconazole and free fluconazole&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients receiving fluconazole as prophylaxis or therapy for an (invasive) fungal&#xD;
        infection at the ICU will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is admitted to an ICU&#xD;
&#xD;
          2. Subject is at least 18 years of age on the day of the first dosing&#xD;
&#xD;
          3. Subject is managed with a central venous or arterial catheter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is known to be hypersensitive to azole antifungal agents&#xD;
&#xD;
          2. Documented history of sensitivity to medicinal products or excipients similar to those&#xD;
             found in the fluconazole preparation&#xD;
&#xD;
          3. Has previously participated in this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Brüggemann, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Muilwijk EW, de Lange DW, Schouten JA, Wasmann RE, Ter Heine R, Burger DM, Colbers A, Haas PJ, Verweij PE, Pickkers P, Brüggemann RJ. Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrob Agents Chemother. 2020 Sep 21;64(10). pii: e00984-20. doi: 10.1128/AAC.00984-20. Print 2020 Sep 21.</citation>
    <PMID>32816723</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>fluconazole</keyword>
  <keyword>invasive fungal infection</keyword>
  <keyword>candidiasis</keyword>
  <keyword>intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

